Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria

Matthew Holt, Daniel Payne, Natalie Fox, Claire McKinley, Morag Griffin, Petra Muus, Talha Munir, Alexandra Pike, Louise Arnold, Sateesh Nagumantry, Richard Kelly, Darren Newton

Blood (2025) 146 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2025-3193

Published: 2025

Journal Articles

Spontaneous remissions in paroxysmal nocturnal hemoglobinuria: True remission or clonal evolution to malignancy?

Caitlin Roger, Matthew Holt, Louise Arnold, Lindsay Mitchell, Sateesh Nagumantry, Katharine Lowndes, Alexandra Pike, Talha Munir, Petra Muus, Morag Griffin, Richard Kelly

Blood (2025) 146 (Supplement 1): 29.

https://doi.org/10.1182/blood-2025-29

Published: 2025

Journal Articles

Clonal architecture and dynamics of somatic evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria

Michael Spencer Chapman, Kudzai Nyamondo, Nicholas Williams, Daniel Leongamornlert, Joanna Baxter, Behnaz Shojaeddin Givi, Matthew Holt, Theodora Foukaneli, Duncan Brian, Chi Wong, Richard Kelly, Darren Newton, Alan Warren, Jyoti Nangalia

Blood (2025) 146 (Supplement 1): 25.

https://doi.org/10.1182/blood-2025-25

Published: 2025

Journal Articles

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

Blood (2025) 146 (Supplement 1): 1427.

https://doi.org/10.1182/blood-2025-1427

Published: 2025

Journal Articles

The use of anticoagulation on paroxysmal nocturnal hemoglobinuria.

Louise Arnold, Petra Muus, Talha Munir, Alexandra Pike, Sateesh Nagumantry, Hussnain Javaid, Matthew Holt, Elizabeth Littlewood, Amy Todd, Emily Groom-White, Morag Griffin, Richard Kelly

Blood (2025) 146 (Supplement 1): 1111.

https://doi.org/10.1182/blood-2025-1111

Published: 2025

Journal Articles

Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria

Matthew Holt, Daniel Payne, Natalie Fox, Claire McKinley, Morag Griffin, Petra Muus, Talha Munir, Alexandra Pike, Louise Arnold, Sateesh Nagumantry, Darren Newton, Richard Kelly

Blood (2025) 146 (Supplement 1): 4973.

https://doi.org/10.1182/blood-2025-4973

Published: 2025

Journal Articles

Paroxysmal nocturnal hemoglobinuria in pediatric patients: A UK experience

Morag Griffin, Malinthi Adikarama, Shreyans Gandhi, Petra Muus, Alexandra Pike, Talha Munir, Matthew Holt, Louise Arnold, Franceso Versino, Joanna Large, Richard Kelly, Austin Kulasekararaj, Roochi Trikha

Blood (2025) 146 (Supplement 1): 4662.

https://doi.org/10.1182/blood-2025-4662

Published: 2025

Journal Articles

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Richard J. Kelly, Matthew Holt, Jennifer Vidler, Louise M. Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Abraham Varghese, John R. Davies, Roochi Trikha, Austin G. Kulasekararaj, Lindsay Mitchell, Shreyans Gandhi

Blood (2024) 143 (12): 1157–1166.

https://doi.org/10.1182/blood.2023021762

Published: 2024

Journal Articles

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Richard Kelly, Matthew Holt, Jennifer Vidler, Louise Arnold, Joanna Large, Briony Forrest, Catherine Barnfield, Alexandra Pike, Morag Griffin, Talha Munir, Petra Muus, Sateesh K. Nagumantry, Roochi Trikha, Austin Kulasekararaj, Lindsay Mitchell, Shreyans Ghandi

Blood (2022) 140 (Supplement 1): 5792–5794.

https://doi.org/10.1182/blood-2022-167725

Published: 2022

Journal Articles

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Darja Karpova, PhD, Julie Ritchey, Matthew Holt, Darlene Monlish, PhD, Laura G. Schuettpelz, MD PhD, Wei Yang, Jean-Pierre Levesque, PhD, Allison Robyn Pettit, PhD BSc, Michael P. Rettig, PhD, Halvard Bonig, MD MA, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2648.

https://doi.org/10.1182/blood.V128.22.2648.2648

Published: 2016

Journal Articles

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Chantiya Chanswangphuwana, MD, Michael P. Rettig, PhD, Walter Akers, Deep Hathi, Matthew Holt, Julie O'Neal, PhD, Julie Ritchey, Danny Kohnen, Justin A King, Michael H. Tomasson, MD, Ravi Vij, MD, Monica Shokeen, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 2056.

https://doi.org/10.1182/blood.V128.22.2056.2056

Published: 2016

Journal Articles

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Darja Karpova, PhD, Michael P. Rettig, PhD, Linda Eissenberg, PhD, Julie Ritchey, Matthew Holt, Richard Heier, Stacy Arnett, PhD, Marvin Meyers, PhD, David W. Griggs, PhD, Peter Ruminski, PhD, Dwight Morrow, PhD, John F DiPersio, MD PhD

Blood (2016) 128 (22): 659.

https://doi.org/10.1182/blood.V128.22.659.659

Published: 2016

Journal Articles

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

Jaebok Choi, PhD, Matthew L Cooper, PhD, Kiran R. Vij, MD, Bing Wang, Julie Ritchey, Bader Alahmari, MD, Matthew Holt, John F DiPersio, MD PhD

Blood (2016) 128 (22): 3353.

https://doi.org/10.1182/blood.V128.22.3353.3353

Published: 2016

Journal Articles

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Mark A. Schroeder, MD, Jaebok Choi, PhD, Matthew L Cooper, PhD, David Schwab, BA CCRP, Sarah Willey, Jingxia (Esther) Liu, PhD, Matthew Holt, Linda Eissenberg, Iskra Pusic, MD, Armin Ghobadi, MD, Rizwan Romee, MD, John S. Welch, MD PhD, Keith Stockerl-Goldstein, MD, Camille N. Abboud, MD FACP, Ravi Vij, MD, Geoffrey L. Uy, MD, Peter Westervelt, MD PhD, John F Dipersio, MD PhD

Blood (2015) 126 (23): 1935.

https://doi.org/10.1182/blood.V126.23.1935.1935

Published: 2015

Journal Articles

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

Armin Ghobadi, MD, Michael P. Rettig, PhD, Matthew Holt, Julie Ritchey, Linda Eissenberg, John F. DiPersio, MD PhD

Blood (2015) 126 (23): 513.

https://doi.org/10.1182/blood.V126.23.513.513

Published: 2015

Journal Articles

Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML

Ambrose Campbell, Ezhilarasi Chendamarai, PhD, Matthew Holt, Julie Prior, Linda Eissenberg, PhD, Michael P. Rettig, PhD, Gregoire Vuagniaux, PhD, Claudio Zanna, PhD, John F. DiPersio, MD PhD

Blood (2014) 124 (21): 5296.

https://doi.org/10.1182/blood.V124.21.5296.5296

Published: 2014

Journal Articles

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

Michael P. Rettig, PhD, Matthew Holt, Julie Prior, Sharon Shacham, PhD, MBA, Michael Kauffman, MD, PhD, Dilara McCauley, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 237.

https://doi.org/10.1182/blood.V122.21.237.237

Published: 2013

Journal Articles

ALT-1188: A New CXCR4 Antagonist In Development For Mobilization Of HSPCs

Michael P. Rettig, PhD, Armin Ghobadi, MD, Matthew Holt, Stephanie Meier, Julie Ritchey, Yesim Tahirovic, PhD, Alexander Bridges, PhD, Doug Gooding, PhD, John F. Dipersio, MD, PhD

Blood (2013) 122 (21): 891.

https://doi.org/10.1182/blood.V122.21.891.891

Published: 2013

Journal Articles

The Effect of Bortezomib (B) Alone or in Combination with Other Agents for Stem Cell Mobilization in Mice

Armin Ghobadi, MD, Matthew Holt, Julie Ritchey, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 583.

https://doi.org/10.1182/blood.V120.21.583.583

Published: 2012

Journal Articles

Bortezomib Can Overcome Stroma-Mediated Chemotherapy Resistance in Acute Lymphoblastic Leukemia.

Ibraheem H. Motabi, MD, Julie Ritchey, Matthew Holt, John F. DiPersio, MD, PhD

Blood (2012) 120 (21): 2475.

https://doi.org/10.1182/blood.V120.21.2475.2475

Published: 2012

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

The effect of breakthrough hemolysis on complement factor h and factor I levels in paroxysmal nocturnal hemoglobinuria

Spontaneous remissions in paroxysmal nocturnal hemoglobinuria: True remission or clonal evolution to malignancy?

Clonal architecture and dynamics of somatic evolution in aplastic anemia and paroxysmal nocturnal hemoglobinuria

Real-world use of oral iptacopan monotherapy in paroxysmal nocturnal hemoglobinuria

The use of anticoagulation on paroxysmal nocturnal hemoglobinuria.

Factor bb as a biomarker during breakthrough hemolysis in paroxysmal nocturnal hemoglobinuria

Paroxysmal nocturnal hemoglobinuria in pediatric patients: A UK experience

Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria

Treatment Outcomes of Complement Protein C5 Inhibition in 509 Patients with Paroxysmal Nocturnal Hemoglobinuria in the United Kingdom

Expansion and Maintenance of Hematopoietic Stem and Progenitor Cells in Course of Long-Term Inhibition of CXCR4/CXCL12 Signaling

Ex Vivo Evaluation of VLA-4 Expression in Primary Human Multiple Myeloma Bone Marrow Samples and In Vivo Mobilization of Murine Multiple Myeloma Cells with Small Molecule VLA-4 Inhibitors

Combined Targeting of CXCR2 and VLA4 Results in Rapid and Synergistic Mobilization of Hematopoietic Stem and Progenitor Cells in Mice

Pharmacologic Co-Blockade of IFNγR and IL6R Pathways to Prevent and Treat GvHD

A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results

Ixazomib, an Oral Proteasome Inhibitor, Induces Rapid Mobilization of Hematopoietic Stem Cells in Mice

Preclinical Studies of the IAP Antagonist Debio 1143 in Combination with Cytarabine or Doxorubicin in a Mouse Model of AML

Inhibition Of Nuclear Transport Modulator Xpo1/CRM1 For The Treatment Of Acute Myeloid Leukemia (AML)

ALT-1188: A New CXCR4 Antagonist In Development For Mobilization Of HSPCs

The Effect of Bortezomib (B) Alone or in Combination with Other Agents for Stem Cell Mobilization in Mice

Bortezomib Can Overcome Stroma-Mediated Chemotherapy Resistance in Acute Lymphoblastic Leukemia.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only